Taken together, these data demonstrated that X-370 significantly inhibited the viability of primary childhood B-ALL cells exhibiting PI3Kδ-dependent Erk1/2 signaling, and that PI3Kδ is a promising therapeutic target against childhood B-ALL. The gene discussed is MAPK3; the disease is precursor B-cell acute lymphoblastic leukemia.